Cargando…

Amyloid-associated increases in longitudinal report of subjective cognitive complaints

INTRODUCTION: To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. METHODS: Two hundred seventy-nine clinically normal older partici...

Descripción completa

Detalles Bibliográficos
Autores principales: Amariglio, Rebecca E., Buckley, Rachel F., Mormino, Elizabeth C., Marshall, Gad A., Johnson, Keith A., Rentz, Dorene M., Sperling, Reisa A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153378/
https://www.ncbi.nlm.nih.gov/pubmed/30258973
http://dx.doi.org/10.1016/j.trci.2018.08.005
Descripción
Sumario:INTRODUCTION: To investigate whether baseline subjective cognitive complaints (SCCs) predict longitudinal decline on neuropsychological testing and whether SCC increases longitudinally, in the setting of high levels of amyloid burden. METHODS: Two hundred seventy-nine clinically normal older participants (mean age = 73.7 ± 6.1 years) from the Harvard Aging Brain Study, a cohort of community-dwelling individuals, were followed longitudinally (4.27 ± 1.35 years) with annual subjective memory questionnaires and neuropsychological assessment. (11)C Pittsburgh compound-B positron emission tomography was used to measure cortical amyloid and to classify status (Aβ+/Aβ−) at baseline. RESULTS: Higher baseline SCC predicted more rapid cognitive decline on neuropsychological measures among those with elevated amyloid (t = −2.18, P < .0001). In addition, longitudinal report of SCC significantly increased over time, with SCC progression most pronounced among Aβ+ individuals (t = 2.24, P = .0005). DISCUSSION: SCC may inform risk for future cognitive decline and track progression of self-perceived decline, particularly in those along the AD trajectory, providing potentially important indicators of clinical meaningfulness in AD prevention trials.